IC
VNDA icon

Innealta Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Innealta Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-134
Closed -$758 – 1644
2024
Q2 		$758 Buy
+134
New +$692 ﹤0.01% 1368

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Innealta Capital's VNDA Position: Q3 2024 in Review

Innealta Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 134 shares — an estimated $758 sold.

Innealta Capital first reported a position in VNDA in Q2 2024 and held it in 1 quarter. The position peaked at $758 in Q2 2024. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

  • Innealta Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 134 Vanda Pharmaceuticals shares in Q3 2024, an estimated $758.
  • Innealta Capital first reported a position in Vanda Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Vanda Pharmaceuticals position peaked at $758 in Q2 2024.
  • 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.